FDG-PET/CT is a standardized imaging technique that has reached a great importance in the management of patients affected by Multiple Myeloma. It is proved, in fact, that it allows a deep evaluation of therapy efficacy and provides several prognostic indexes both at stag-ing and after therapy. For this reason, it is now recognised as a gold standard for therapy assessment. Beside this, in reacent years FDG-PET/CT contribution to the understanding of Multiple Myeloma has progressively grown. Papers have been published analyzing the prognostic value of active disease volume measurement and standardization issues, the meaning of FDG positive paramedullary and extrameduallary disease, the prognostic impact of FDG positive minimal residual disease, the relation between focal lesions and clonal eterogenity of this disease and the comparison with whole body DWI-MR in terms of detec-tion and therapy assessment. These newer aspects not of clinical impact yet, of FDG-PET/ CT in Multiple Myeloma will be presented and discussed in this review. Semin Nucl Med 53:352-370 (c) 2022 Published by Elsevier Inc.
Bezzi, D., Ambrosini, V., Nanni, C. (2023). Clinical Value of FDG-PET/CT in Multiple Myeloma: An Update. SEMINARS IN NUCLEAR MEDICINE, 53(3), 352-370 [10.1053/j.semnuclmed.2022.10.008].
Clinical Value of FDG-PET/CT in Multiple Myeloma: An Update
Bezzi, Davide;Ambrosini, Valentina;
2023
Abstract
FDG-PET/CT is a standardized imaging technique that has reached a great importance in the management of patients affected by Multiple Myeloma. It is proved, in fact, that it allows a deep evaluation of therapy efficacy and provides several prognostic indexes both at stag-ing and after therapy. For this reason, it is now recognised as a gold standard for therapy assessment. Beside this, in reacent years FDG-PET/CT contribution to the understanding of Multiple Myeloma has progressively grown. Papers have been published analyzing the prognostic value of active disease volume measurement and standardization issues, the meaning of FDG positive paramedullary and extrameduallary disease, the prognostic impact of FDG positive minimal residual disease, the relation between focal lesions and clonal eterogenity of this disease and the comparison with whole body DWI-MR in terms of detec-tion and therapy assessment. These newer aspects not of clinical impact yet, of FDG-PET/ CT in Multiple Myeloma will be presented and discussed in this review. Semin Nucl Med 53:352-370 (c) 2022 Published by Elsevier Inc.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
